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Abstract
Background: Metallothionein 1H (MT1H) expression level is downregulated in several kinds of tumors, including
hepatocellular cancer (HCC). However, its biological functions and underlying mechanisms in HCC is largely
unknown. The current study aimed to demonstrate the expression status, biological roles and potential mechanisms of
MT1H in HCC.
Methods: We investigated the expression level of MT1H in the Cancer Genome Atlas (TCGA) dataset and a panel of 12
paired tumor/non-tumor tissues. In vitro, gain-of-function experiments were performed to examine the role of MT1H
on HCC cell proliferation, invasion, and migration. Using bioinformatics assay, reporter assays, quantitative real-time
PCR, and western blotting, we explored the possible mechanisms underlying the role of MT1H in HCC cells. In vivo
nude mice experiments were performed to assess the anti-proliferative role of MT1H in HCC.
Results: Downregulation of MT1H was observed in TCGA dataset and a panel of 12 paired tumor/non-tumor tissues.
Ectopic overexpression of MT1H in HepG2 and Hep3B cells inhibited cell proliferation, invasion, and migration. Gene
Set Enrichment Analysis (GSEA) showed that MT1H might involve in regulation of Wnt/β-catenin pathway. Top/Fop
reporter assay confirmed that MT1H had an effect on Wnt/β-catenin signaling. Real-time PCR showed MT1H expression
decreased the expression of Wnt/β-catenin target genes. Western blotting assay showed that overexpression of MT1H
inhibited the nuclear translocation of β-catenin and that the Akt/GSK-3β axis mediated the modulatory role of MT1H
on Wnt/β-catenin signaling in HCC. In vivo nude mice experiments demonstrated that MT1H suppressed the proliferation
of HCC cells. Taken together, MT1H suppressed the proliferation, invasion and migration of HCC cells via regulating Wnt/
β-catenin signaling pathway.
Conclusions: This study demonstrated that through inhibiting Wnt/β-catenin pathway, MT1H suppresses the proliferation
and invasion of HCC cells. MT1H may be a potential target for HCC therapy.
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Background
Hepatocellular cancer (HCC), the third cause of cancer-
related death worldwide, accounts for 85%-90% of all
primary liver cancer [1, 2]. In China, it is the most com-
monly diagnosed cancer and the leading cause of cancer
death in male patients younger than 60 years old [3].
Although there are various treatment options, such as
surgical resection, liver transplantation, interventional
treatment, and systemic therapies, the outcomes of patients
with advanced stage are still extremely poor [4, 5]. Con-
ventional cytotoxic systemic therapy is of limited bene-
fit for unresectable or metastatic HCC [6]. Sorafenib, a
molecular-targeted agent, demonstrates a modest overall
survival benefit, however resistance develops eventually
[6–8]. Deeper understanding of molecular carcinogenesis
of HCC is urgently warranted to develop new novel target
agents.
The metallothioneins (MTs) are a class of cysteine-rich,
low-molecular-weight, metal-binding intracellular proteins,
including four identified isoforms (MT-1, MT-2, MT-3, and
MT-4) [9, 10]. In human, these proteins are encoded by a
cluster of genes, which are located on chromosome 16q13
[11]. The MT-1 protein comprises many subtypes encoded
by a set of MT-1 genes (MT1A, MT1B, MT1E, MT1F,
MT1G, MT1H, etc.). MT-1 genes are reported to be in-
volved in carcinogenesis in various human tumors [9].
In Fu et al’s study [12], MT1G acts as a tumor suppressor in
thyroid carcinogenesis via regulating the phosphatidylinositol-
3-kinase (PI3K)/Akt pathway and Rb/E2F pathway. Loss of
heterozygosity (LOH) causes the downregulation of MT1F in
colon cancer tissues, suggesting a tumor suppressor role for
MT1F in colon cancer [13]. Of specific note, by analyz-
ing 30 sets of online microarray data, Han et al. [14]
found a consistent downregulation of MT1H in various
kinds of human malignancies as compared with normal
tissues, including small cell lung cancer, neuroblastoma,
melanoma, B-cell lymphoma, prostate cancer, colon cancer,
breast cancer, and leukemia. Furthermore, a 10- to 100-fold
decrease of MT1H expression was observed in HCC in
comparison with normal liver tissues, indicating a potential
role of MT1H in the development and progression of HCC
[14]. Nevertheless, the biological functions and underlying
mechanisms of MT1H in HCC are largely unknown.
The Wnt/β-catenin signaling pathway is frequently ac-
tivated during carcinogenesis, especially in HCC [15]. In
the canonical Wnt pathway, Wnt binding to Fz receptor
inactivates the β-catenin destruction complex of aden-
omatous polyposis coli (APC), axin, and glycogen synthase
kinase-3 β (GSK-3β) [15]. When the Wnt pathway is
activated, β-catenin is released from the complex and
translocated into nucleus. The nuclear β-catenin binds
to members of the lymphoid-enhancing factor/T-cell
factors (LEF/TCF) family that activate target genes tran-
scription [16]. Further delineation of the mechanisms
underlying the dysregulated Wnt/β-catenin signaling in
HCC is of great interest.
In the current study, we identified the biological func-
tions of MT1H in HCC and explored the possible mecha-
nisms. Our study suggests that MT1H plays crucial role in
regulating the proliferation and invasion of HCC cells
through modulating Wnt/β-catenin signaling.
Methods
Cells and culture
Human hepatoblastoma cell lines HepG2 and Hep3B
were obtained from the China Infrastructure of Cell Line
Resource. The cells were cultured in Dulbecco’s modified
Eagles medium (DMEM) (Gibco, Grand Island, NY) con-
taining 10% fetal bovine serum (FBS), 100 U/mL penicil-
lin, and 100 mg/mL streptomycin (Gibco, Grand Island,
NY) at 37 °C in a humidified atmosphere with 5% CO2.
Obtainment of clinical specimens
Twelve HCC tissues (T) and their corresponding adjacent
non-tumorous liver tissues (NT) were obtained from the
surgery operation in the First Affiliated Hospital of
Zhejiang University from Jan. 2015 to Dec. 2015. NT
was defined as liver tissues more than 2 cm away from
the edge of the tumor [17]. Two pathologists carried
out histopathological diagnosis of the specimens inde-
pendently. Soon after the tissues were collected, they
were immediately snap-frozen in liquid nitrogen and
stored at −80 °C for subsequent total cellular RNA ex-
traction. The clinicopathologic characteristics of the pa-
tients are listed in Table 1. This study was performed in
accordance with the ethical guidelines of the Declar-
ation of Helsinki and was approved by the hospital’s In-
stitutional Review Board (No. 2016397). Informed
consent was obtained from each patient.
Table 1 The characteristics of patients (n = 12)
Clinical characteristics Patients (n, %)
Age (yr) ≤50 4 (33.3)
>50 8 (66.7)
Gender Male 9 (75)
Female 3 (25)
BCLC stage Stage 0-A 3 (25)
Stage B 7 (58.3)
Stage C-D 2 (16.7)




Liver cirrhosis No 2 (16.7)
Yes 10 (83.3)
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Generation of stable cell lines with MT1H overexpression
Human TrueORF Gold™ pCMV6-Entry-MT1H plasmid
with a C-terminal fusion of MYC/DDK tag was pur-
chased from OriGene Technologies (Rockville, MD). To
establish stable cell lines with constitutive expression of
MT1H, HepG2 and Hep3B cells were transfected with
pCMV6-Entry-MT1H by Lipofectamin™ 2000 (Invitro-
gen, Life Technology, Carlsbad, CA) according to the
manufacturer’s protocol. After selection with complete
medium containing G418 (0.6 mg/mL) for 2 weeks [18],
individual clones were isolated and grown separately in
the presence of G418. The expression of MT1H was
confirmed by Western blotting assay. A stable transfect-
ant expressing pCMV6-Entry empty vector was estab-
lished and served as the control.
Transwell invasion and migration assays
For Transwell invasion/migration assays, the indicated
2 × 104 cells suspended in 200 μL DMEM without FBS
were added to Transwell insert (Millipore, Billerica, MA)
with or without coated Matrigel (BD Biosciences San
Diego, CA), respectively. The insert held in 24-well com-
panion plates with DMEM containing 10% FBS. After
24 h incubation, the cells and Matrigel in the upper
chambers were removed by cotton tip. Migrating and in-
vading cells at the bottom of the filter were fixed, stained
with 1.0% crystal violet solution and photographed
under a light microscope. The number of migrating and
invading cells was quantified by counting five fields in
each chamber [19]. This experiment was repeated three
separate times.
Wound healing assay
To evaluate the cell motility, the wound-healing assay
was performed. Indicated cells were seeded in 6-well
plates and grown into a monolayer. In order to exclude
the possible role of MT1H in proliferation that may
affect the result of wound healing assay, the cells were
cultured in DMEM medium supplemented with lower
percentage of serum (3%). A sterile p200 pipette tip was
used to make a scratch and the cells were rinsed several
times with medium to remove debris and unattached
cells. Cells were then cultured for 36 h and the motility
of cells was photographed. Migratory activity of the indi-
cated cells was assessed by the width of the wound, and
results were quantified as the percent of control [20].
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-
tetrazolium bromide) assay
HepG2-Vector, HepG2-MT1H, Hep3B-Vector and Hep3B-
MT1H cells were trypsinized and seeded in 96-well plates
at a density of 2 × 103 cells/well. A solution of MTT
(Sigma-Aldrich, St Louis, MO, 25 μL of a 5 mg/mL so-
lution in PBS) was added and cells were incubated for
another 2 h at 37 °C. Then the medium was replaced
by 100 μL Dimethyl sulfoxide (DMSO, Sigma-Aldrich,
St Louis, MO) and shaken at room temperature for
10 min. The plate absorbance was measured at 490 nm.
This experiment was repeated three separate times.
Colony formation assay
Two hundred indicated cells per well were put in 12-
well plates and cultured in complete medium for 10 days.
The colonies were fixed with 4% paraformaldehyde and
stained with 1% crystal violet solution [21]. This experi-
ment was repeated three separate times.
5-Ethynyl-2′-deoxyuridine (EdU) incorporation assay
EdU incorporation assay was carried out using the Cell-
Light™ EdU In Vitro kit (RiboBio, Guangzhou, China)
according to the manufacturer’s instructions. Briefly, the
indicated cells added with EdU (50 μM) were cultured
for 2 h, and then fixed in 4% paraformaldehyde at room
temperature for 30 min. TritonX (0.5%) was used to
permeabilize the cells. After incubated with 1 × Apollo
reaction mixture for 30 min, the cells were subsequently
stained with Hoechst 33342 for 30 min at room temperature
[22]. EdU positive cells were calculated with Zeiss fluores-
cent microscope system (Carl Zeiss, Thornwood, NY). This
experiment was repeated three separate times.
Western blotting assay
Briefly, the indicated cells were washed with PBS and
lysed using Radioimmunoprecipitation assay buffer
(RIPA) (150 mM NaCl, 1% NP-40, 0.5% Sodium deoxy-
cholate, 0.1% SDS, 50 mM Tris–HCl pH 7.4) and the
amounts of protein were assayed using the Bradford
method. Equal amount of protein was subjected to so-
dium dodecyl sulfate-polyacrylamide gels electrophoresis
(SDS-PAGE). Proteins on the gel were transferred onto a
polyvinylidene difluoride (PVDF) membrane (Millipore,
MA). The membrane was blocked in 5% powdered non-
fat milk in Tris-buffered saline (TBS) solution containing
0.05% Tween 20 for 1 h. Membrane was then incubated
with primary antibody overnight at 4 °C, followed by
incubation with secondary antibody conjugated to
horseradish peroxidase at room temperature for 1 h.
The signal was developed using the enhanced chemi-
luminescence (ECL, Advance Western blotting detec-
tion kit, Pierce, Rockford, IL) to expose an Xray film.
The primary antibodies against Flag, β-catenin, lamin
a, α-Tubulin (Abcam, Cambridge, UK), phospho-Akt
(Ser473), Akt, phospho-GSK-3β (Ser9), and GSK-3β
(Cell Signaling Technology, Beverly, MA), were used.
The experiment was repeated three times to confirm
the results. The intensity of the indicated bands was
quantified using Quantity One software (Bio-Rad,
Richmond, CA).
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Immunofluorescence
Indicated cells were grown on coverslip (Fisher Scientific,
Pittsburgh, PA) on 24-well plate were fixed with 4% para-
formaldehyde and permeabilized with 0.1% Triton-X in
PBS. β-catenin were detected by incubation with specific
anti-β-catenin antibody (Abcam, Cambridge, UK) over-
night at 4 °C. A secondary antibody (donkey anti-rabbit
rhodamine red) (Jackson Immunoresearch Laboratories,
West Grove, PA) was used before staining the nuclei with
1 μg/mL DAPI (Sigma-Aldrich, St. Louis). Pictures were
acquired by using a fluorescence microscope (Olympus,
Tokyo, Japan).
Quantitative real-time PCR (qPCR) analysis
Total RNA was extracted from the cells or tissues using
Trizol reagent (Invitrogen, Life Technology, Carlsbad,
CA), and reverse transcription was conducted as follows
with random primers and Moloney murine leukemia
virus reverse transcriptase (Promega, Madison, Wisconsin)
in accordance with the manufacturer’s protocol. The ori-
ginal amount of the specific transcripts were measured by
real-time PCR according to a standard protocol with a
SYBR Green PCR kit (Roche Diagnostics, Indianapolis, IN)
using the ABI Prism 7000 sequence detection system
(Applied Biosystems, Foster City, CA). For each gene
and sample, three independent assays were conducted
and the comparative Ct method was performed to cal-
culate the relative abundance of mRNA compared with
that of the endogenous reference control β-actin. The
primers used were listed in Table 2.
Nuclear protein extraction
Nuclear protein extraction was carried out using Active
Motif Nuclear Extraction Kit (Active Motif, Carlsbad,
CA) according to the manufacture’s protocol. Lamin A
was used as nuclear fraction controls [23].
Luciferase reporter assay
The Top/Fop flash plasmid system (Upstate, Lake Placid,
NY) was used to evaluate the transcriptional activity of
TCF. Topflash and Fopflash plasmids were co-transfected
in the indicated cells using Lipofectamin™ 2000 (Invitrogen,
Life Technology, Carlsbad, CA). The luciferase values were
measured after 48 h incubation, using Dual-Luciferase re-
porter assay system (Promega, Madison, WI) according to
the manufacturer’s instructions [24]. The experiment was
repeated three times to confirm the results.
In vivo tumorigenicity assay
HepG2-Vector and HepG2-MT1H (1.5 × 106 cells) were
injected subcutaneously into the right flanks of female
BALB/c athymic nude mice (4–6 weeks of age), five
mice per group [25]. The tumor volume was measured
routinely using a caliper every 5 days, and was calculated
with the formula 0.5 × (length × width2). At 30 days after
injection, all mice were sacrificed and tumors were weighted.
This experiment was performed in accordance with the in-
stitutional ethical guidelines for animal experiment.
Gene set enrichment analysis (GSEA)
GSEA (http://software.broadinstitute.org/gsea/index.jsp)
was performed as previously described [26]. We used
LIHC RNA-seq data generated by the Cancer Genome
Atlas (TCGA) and sorted the samples into the top
and bottom quartiles of MT1H expression (high and
low MT1H expression, respectively). Analyzed gene
sets (PID_WNT_CANONICAL_PATHWAY [27] and
WNT_SIGNALING (http://software.broadinstitute.org/
gsea/msigdb/cards/WNT_SIGNALING.html) were down-
loaded from GSEA and the genes are listed in Additional
file 1: Table S1. To assess the enrichment, the absolute
value of the GSEA metric (Pearson correlation) was
considered for deregulated genes.
Statistical analysis
All statistical analyses were performed using the SPSS
13.0 package (SPSS International, Chicago, IL, USA).
Continuous variables were presented as mean ± SD and
analyzed using the Student’s t-test. The relationship
between MT1H expression and the expression of Wnt/
β-catenin target genes was analyzed by Chi-square
tests. P < 0.05 was considered statistically significant.
Results
MT1H expression in human HCCs
To explore the role of MT1H in HCC, we analyzed the
MT1H expression in large datasets derived from TCGA
databases [26]. TCGA is a collaboration of the National
Cancer Institute (NCI) and National Human Genome
Research Institute (NHGRI) [26]. TCGA contains multi-
dimensional and comprehensive maps of the key gen-
omic changes in various types of cancer, including HCC.
The results from TCGA RNASeq2 data showed that in
50 pairs of HCC tissues (T) and their corresponding ad-
jacent non-tumorous liver tissues (NT), MT1H is signifi-
cantly downregulated in most (48/50) HCCs (Fig. 1a).
The clinical data of these 50 patients are shown in
Additional file 2: Table S2. Furthermore, we expanded
our investigation to clinical samples in order to assess
Table 2 Sequences of primers
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the expression level of MT1H in 12 human HCCs by
qRT-PCR. As shown in Fig. 1b, MT1H expression level
was found to be markedly decreased in all HCC tu-
mors as compared with the adjacent non-tumorous
liver tissues. These results suggest that MT1H expres-
sion is downregulated in human HCCs and may play a
role in hepatocellular carcinogenesis.
MT1H suppresses the growth of HepG2 and Hep3B cells
To examine the potential role of MT1H in hepatocellu-
lar carcinogenesis, we sought to assess the effect of
MT1H on the growth of HCC cells. HepG2 and Hep3B
cells were stably transfected with full length Flag-tagged
MT1H and immunoblots were performed to confirm the
overexpression of MT1H (Fig. 2a). As shown in Fig. 2b,
ectopic overexpression of MT1H in HepG2 and Hep3B
cells significantly inhibited the MTT response as com-
pared with that of empty vector control cells. Next, we
examined the effects of enforced expression of MT1H
on the colony forming capability of HCC cells. As shown
in Fig. 2c, enforced expression of MT1H in HepG2 and
Hep3B cells decreased more than 50% in colony num-
bers as compared with the control cells. Moreover, in
Edu incorporation assay, the DNA synthesis capability
was significantly decreased in MT1H-overexpressed cells
(Fig. 2d). The results of these experiments demonstrate
that enforced expression of MT1H in HCC cells is cor-
related with impaired cell growth and DNA synthesis.
MT1H suppresses tumor cell invasiveness and motility
The effect of MT1H overexpression on invasiveness and
migration ability of HepG2 and Hep3B cells was studied.
The matrigel-coated transwell assay was performed and
the number of MT1H overexpressed cells in the bottom
well was significantly reduced compared with the control
cells, which indicated that MT1H may suppress the cell
invasion (Fig. 3a and b, left). Likewise, the matrigel-
uncoated transwell assay showed that ectopic overex-
pression of MT1H significantly impaired the migration
capability of hepatoma cells as compared with the vector
control cells (Fig. 3a and b, right). Furthermore, scratch
and wound healing assay indicated that enforced expres-
sion of MT1H significantly inhibited the migration of
HepG2 and Hep3B (Fig. 3c and d). Taken together, these
results suggest that MT1H can affect the invasiveness
and migration of human HCC cells.
MT1H suppresses the Wnt/β-catenin signaling via
inhibiting nuclear translocation of β-catenin
Next, we sought to explore the driving mechanisms
behind the effects of MT1H on HCC cell proliferation,
invasion as well as migration. We used LIHC RNAseq2
data generated by the TCGA and sorted the samples into
the top and bottom quartiles of MT1H expression (high
and low MT1H expression, respectively). By using TCGA
dataset and the GSEA assay, we found that Wnt/β-catenin
pathway related genes were significantly enriched in the
HCC patients with low MT1H expression (Fig. 4a). More-
over, we analyzed whether the association between the
MT1H expression and Wnt/β-catenin target genes (http://
web.stanford.edu/group/nusselab/cgi-bin/wnt/) expression
can be found in TCGA data. We categorized the Wnt/
β-catenin target genes’ expression into two groups: low
expression group (less than the median; n = 50) and high
expression group (greater than the median; n = 50). As
shown in Additional file 3: Figure S1a and Additional file 4:
Table S3, significantly higher levels of POU5F1, DKK1,
NOS2, MSL1, MYCBP, NRCAM, LEF1, and PPARD
transcripts were found in HCC tissues versus adjacent
non-tumorous liver tissues. Taken together, these data
suggest that MT1H plays a potential role in regulating
β-catenin signaling in HCC.
Next, qPCR was performed and the results showed
that ectopic overexpression of MT1H in HepG2 and
Hep3B cells significantly suppressed the levels of MYC,
MMP7, and LEF1 (Fig. 4b). To further confirm whether
MT1H regulates the Wnt/β-catenin signaling, luciferase
assay of β-catenin reporter (TOP/FOP) was conducted.
Fig. 1 Low expression level of MT1H in HCC patients. a The expression of MT1H in 50 pairs of primary HCC tumors versus paired non-tumorous
liver tissues mined from RNAseqV2 data set on TCGA. b The log2Tumor/Non-tumorous change of MT1H expression in 12 paired fresh HCC tissues
and the adjacent non-cancerous liver tissues
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As shown in Fig. 4c, MT1H inhibited the Wnt/β-catenin
transcriptional activity in HepG2 and Hep3B cells. As
expected and shown in Fig. 4d, e, and Additional file 3:
Figure S1b, β-catenin nuclear translocation was signifi-
cantly attenuated in MT1H over-expressed HCC cells in
comparison with the control cells. Next, we explored the
mechanisms of MT1H regulating the β-catenin signal-
ing. We found that the phosphorylation of Akt was sig-
nificantly inhibited by MT1H overexpression (Fig. 4f and
Additional file 3: Figure S1c). It has been well known
that Akt can lead to phosphorylated inactivation of
GSK-3β, and thereby resulting in β-catenin stabilization
and nuclear transportation. As expected, the dephos-
phorylation of Akt reduced phosphorylation of GSK-3β
(Fig. 4f and Additional file 3: Figure S1c), suggesting the
Akt/GSK-3β axis mediates the modulatory role of
MT1H on Wnt/β-catenin signaling in HCC. Collectively,
these data indicate that Wnt/β-catenin signaling is a tar-
get downstream of MT1H in HCC.
MT1H overexpression attenuates tumorigenicity in nude
mice
To further assess the effect of MT1H overexpression on
tumorigenicity in vivo, we subcutaneously injected
HepG2-Vector and HepG2-MT1H cells into the nude
mice. Intriguingly, as shown in Fig. 5a and b, the tumors
formed by HepG2-MT1H cells were significantly smaller
than that of control cells. The average tumor weight of
the MT1H- transfected cells inoculated mice was signifi-
cantly decreased as compared with that of control cells,
at day 30 (Fig. 5c).
Discussion
In the present study, we found significantly downregulated
MT1H in HCC tissues, which is consistent with previous
study [14]. Moreover, MT1H plays an anti-proliferative
and anti-invasive role in HCC cells. MT1H in HCC can
inhibit Wnt/β-catenin signaling, therefore suppresses
HCC progression.
MTs are demonstrated to be involved in various
physiological and pathological processes, such as protection
against oxidative damage, cell proliferation, and apoptosis
[11, 28]. Of note, the important roles of MTs in cancer de-
velopment and progression have been emphasized [29–32].
MT1H, one member of MT-1 genes, has been proved of
decreased expression in HCC tissue [14]. Consistently, the
results in current study from TCGA database and paired
fresh tumor/non-tumor tissues showed significantly de-
creased MT1H expression in HCC tissues. The significant
downregulation of MT1H in HCC implicates its potential
roles in the development and progression of HCC. As ex-
pected, our results indicated that ectopic overexpression of
Fig. 2 MT1H plays a pivotal role in HCC cell proliferation. a Expression of MT1H-Flag in indicated cells. Protein extracts from indicated cells were
immunoblotted with antibody for Flag. α-Tubulin as a loading control. b HepG2-Vector, HepG2-MT1H, Hep3B-Vector, and HepG3B-MT1H cells was
measured by MTT response. Error bars indicate standard deviation (Student’s t-test; *, P < 0.05). c Colony number of MT1H overexpressing HepG2
and Hep3B cells was significantly decreased as compared with respective vector-control. Error bars indicate standard deviation (Student’s t-test; *,
P < 0.05). d Edu incorporation analysis indicates that MT1H suppresses the proliferation of HCC cells. Error bars indicate standard deviation
(Student’s t-test; *, P < 0.05)
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MT1H may inhibit the growth of HCC cells. Moreover,
MT1H involves in the invasiveness of HCC cells.
The mechanisms underlying the downregulation of
MTs have been investigated in malignant diseases
[12–14, 29, 33–40]. The downregulation of MT1F in
colon cancer is mainly caused by loss of heterozygosity
(LOH) [13]. In addition, a direct relation between p53
and MT-1A and MT-2A was found in epithelial cancer
cells [41]. Whether these mechanisms or other mech-
anism are involved in the downregulation of MT1H in
HCC need to be further explored. Delineating the
precise molecular mechanisms for the altered expres-
sion of MT1H in HCC will put new insights into the
understanding of HCC tumorigenesis.
Given that Wnt/β-catenin pathway plays an essential
role in tumorigenesis, together with our bioinformatics
analysis implicated that Wnt/β-catenin signaling might
involve in the function of MT1H in HCC. It is important
to explore the tumor suppressor role of MT1H mediated
by Wnt/β-catenin signaling in HCC. We found that
MT1H suppressed β-catenin nuclear translocation and
transcriptional activity in HCC. Wnt/β-catenin signaling
Fig. 3 MT1H suppresses the invasion and migration of HCC cells. a and b (left) Matrigel invasion assay showed that invading number of MT1H
overexpressing HCC cells was lower than vector-controls. Error bars indicate standard deviation (Student’s t-test; *, P < 0.05). a and b (right) Transwell
migration assay showed that MT1H expression inhibited the migration capability of HCC cells. Error bars indicate standard deviation (Student’s t-test; *,
P < 0.05). c and d Wound healing assay indicated that MT1H expression inhibited HepG2 and Hep3B cell migration
Zheng et al. BMC Cancer  (2017) 17:161 Page 7 of 11
has demonstrated to have important effects on prolifer-
ation and invasion of tumor cells. The activated Wnt/β-
catenin pathway has been observed in at least one-third
HCCs and most of them have mutations in the β-
catenin gene [42]. Therefore, it is rational to deduce
that tumor suppressive role of MT1H on HCC is attrib-
uted, at least partly, to the inhibition of Wnt/β-catenin
signaling.
Fig. 4 MT1H regulates Wnt/β-catenin signaling in HCC cells. a GSEA analysis showed that MT1H might has a regulative role in Wnt/β-catenin
signaling in HCC cells. b qRT-PCR analysis was used to detect the mRNA levels of MYC, MMP7, and LEF1 in indicated cells. Error bars indicate
standard deviation (Student’s t-test; *, P < 0.05). c Wnt/β-catenin signaling activity was assessed by TOP/FOP flash dual-luciferase reporter assay in
indicated cells. Error bars indicate standard deviation (Student’s t-test; *, P < 0.05). d Immunofluorescence of β-catenin distribution in indicated
cells. e Western blot analysis of nuclear extraction from indicated cells. f Western blot analysis was used to detected the level of p-Akt (Ser 473),
total-Akt, p-GSK-3β (Ser 9), and total-GSK-3β in indicated cells. α-Tubulin as a loading control
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Akt can lead to phosphorylated inactivation of GSK-3β,
which in turn results in β-catenin stabilization and nuclear
transportation [43]. Of note, Akt signaling has been im-
plicated in mediating the biological functions of MTs
[12, 44, 45]. These prompt us to investigate whether
MT1H regulates Wnt/β-catenin via Akt/GSK-3β axis.
Intriguingly, our results implicate that Akt/GSK-3β axis
mediates the modulatory role of MT1H on Wnt/β-ca-
tenin signaling. These provide new insights into regula-
tory networks for dysregulated Akt activation in HCC.
Nevertheless, whether MT1H regulates Akt by direct or
indirect mechanisms needs to be further explored. More-
over, Han et al. have reported that MT1H interacted with
euchromatin histone methyltransferase 1 (EHMT1) and
enhanced its methyltransferase activity on histone 3,
thereby involved the tumorigenesis of prostate cancer
[14]. It remains to be determined whether this mechan-
ism or other mechanisms may also be involved in the
role of MT1H in HCC.
Conclusions
In summary, our data showed that through inhibiting
Wnt/β-catenin pathway, MT1H could suppress the pro-
liferation and invasion of HCC cells. MT1H might be a
potential new target for HCC therapy. Ongoing studies
are to explore the molecular mechanism of downregu-
lated MT1H and the interaction between MT1H and
Akt/GSK-3β/β-catenin signaling.
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DKK1, NOS2, MSL1, MYCBP, NRCAM, LEF1, and PPARD transcripts in HCC
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tion of indicated protein levels normalized to control using Bio-Rad
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t-test; *, P < 0.05). (TIF 379 kb)
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Abbreviations
APC: Adenomatous polyposis coli; BCLC: Barcelona Clinic Liver Cancer;
DKK1: Dickkopf WNT Signaling Pathway Inhibitor 1; DMEM: Dulbecco
minimum essential medium; DMSO: Dimethyl sulfoxide; ECL: Enhanced
chemiluminescence; EDU: 5-Ethynyl-2′-deoxyuridine; FBS: Fetal bovine serum;
GSEA: Gene set enrichment analysis; GSK3beta: Glycogen synthase kinase-3
beta; HCC: Hepatocellular cancer; LEF: Lymphoid-enhancing factor; LOH: Loss
of heterozygosity; MMP: Matrix metallopeptidase; mRNA: messenger RNA;
MSL1: Male specific lethal 1; MT: Metallothionein; MT1H: Metallothionein 1H;
MTT: 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide; MYC:
V-myc avian myelocytomatosis viral oncogene; MYCBP: MYC binding protein;
NOS2: Nitric oxide synthase 2; NRCAM: Neuronal cell adhesion molecule;
PCR: Polymerase chain reaction; PI3K: Phosphatidylinositol-3-kinase;
POU5F1: POU class 5 homeobox 1; PPARD: Peroxisome proliferator activated
receptor delta; PVDF: Polyvinylidene difluoride; RIPA: Radioimmunoprecipitation
assay buffer; SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gels; TBS:




Zhejiang Provincial Natural Science Fund (LY13H160007 and LY15H160018),
and Zhejiang Medicines & Health Science and Technology Project
(201348801) supported this research.
Availability of data and materials
All data generated or analyses during this study are included in this article
and its Additional files.
Authors’ contributions
ZY and JL performed and analyzed the experiments and draft the
manuscript. ZX and ZJ designed and analyzed the experiments and revised
the drafting of the manuscript. XC and HY analyzed the data and helped to
prepare the manuscript. XN designed the experiment. All authors have read
and approved the final manuscript.
Fig. 5 MT1H suppresses tumorigenicity in vivo. a Tumor growth curves measured after subcutaneous injection of HepG2-Vector and HepG2-
MT1H. The tumor volume was calculated every 5 days. Error bars indicate standard deviation (Student’s t-test; *, P < 0.05, n = 5). b Photographs of
dissected tumors from nude mice. c Weight of tumors from mice with HepG2-Vector or HepG2-MT1H implantation. Error bars indicate standard
deviation (Student’s t-test; *, P < 0.05, n = 5)
Zheng et al. BMC Cancer  (2017) 17:161 Page 9 of 11
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The use of clinical specimens and clinical data were reviewed and approved
by the institutional ethics committee of the First Affiliated Hospital of
Zhejiang University School of Medicine (Reference No. 2016397). All patients
provided informed consent to participate in this study. All mouse
experiments were performed in accordance with the Principles of Laboratory
Animal Care of the National Institutes of Health and were approved by the
institutional ethics committee of the First Affiliated Hospital of Zhejiang
University School of Medicine (Reference No. 2016340).
Author details
1Department of Medical Oncology, The First Affiliated Hospital, School of
Medicine, Zhejiang University, Hangzhou 310003, China. 2Department of
Neurology, The Children’s Hospital, School of Medicine, Zhejiang University,
Hangzhou 31006, China. 3Department of Hematology, The First Affiliated
Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
4Department of Respiratory Diseases, The First Affiliated Hospital, School of
Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang
310003, China. 5Department of Gynecology, The First Affiliated Hospital,
School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou,
Zhejiang 310003, China.
Received: 26 July 2016 Accepted: 15 February 2017
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;
65:5–29.
2. Schutte K, Schulz C, Malfertheiner P. Hepatocellular Carcinoma: Current
Concepts in Diagnosis, Staging and Treatment. Gastrointest Tumors. 2014;1:
84–92.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J.
Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:
1245–55.
5. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors:
from bench to bedside. J Hematol Oncol. 2013;6:27.
6. Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for
hepatocellular carcinoma: New advances and challenges. World J Hepatol.
2015;7:787–98.
7. Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera
G, Bertino N, Malaguarnera M, Malaguarnera M, Di Carlo I. Hepatocellular
carcinoma: novel molecular targets in carcinogenesis for future therapies.
Biomed Res Int. 2014;2014:203693.
8. You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W,
Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T. Metformin sensitizes sorafenib
to inhibit postoperative recurrence and metastasis of hepatocellular
carcinoma in orthotopic mouse models. J Hematol Oncol. 2016;9:20.
9. Thirumoorthy N, Shyam Sunder A, Manisenthil Kumar K, Senthil Kumar M,
Ganesh G, Chatterjee M. A review of metallothionein isoforms and their role
in pathophysiology. World J Surg Oncol. 2011;9:54.
10. Takahashi S. Molecular functions of metallothionein and its role in
hematological malignancies. J Hematol Oncol. 2012;5:41.
11. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and
potential roles in carcinogenesis. Mutat Res. 2003;533:201–9.
12. Fu J, Lv H, Guan H, Ma X, Ji M, He N, Shi B, Hou P. Metallothionein 1G
functions as a tumor suppressor in thyroid cancer through modulating the
PI3K/Akt signaling pathway. BMC Cancer. 2013;13:462.
13. Yan DW, Fan JW, Yu ZH, Li MX, Wen YG, Li DW, Zhou CZ, Wang XL, Wang
Q, Tang HM, Peng ZH. Downregulation of metallothionein 1F, a putative
oncosuppressor, by loss of heterozygosity in colon cancer tissue. Biochim
Biophys Acta. 2012;1822:918–26.
14. Han YC, Zheng ZL, Zuo ZH, Yu YP, Chen R, Tseng GC, Nelson JB, Luo JH.
Metallothionein 1 h tumour suppressor activity in prostate cancer is
mediated by euchromatin methyltransferase 1. J Pathol. 2013;230:184–93.
15. Klaus A, Birchmeier W. Wnt signalling and its impact on development and
cancer. Nat Rev Cancer. 2008;8:387–98.
16. Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL. Inhibition of the Wnt/
beta-catenin signaling pathway improves the anti-tumor effects of sorafenib
against hepatocellular carcinoma. Cancer Lett. 2016;381:58–66.
17. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, Qiu B, Li Y, Guo L, Wu M,
Feng G, Zou D, Wang H. Prognostic significance of AMPK activation and
therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer
Res. 2013;19:5372–80.
18. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri
H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen
receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001;
276:9817–24.
19. Valster A, Tran NL, Nakada M, Berens ME, Chan AY, Symons M. Cell
migration and invasion assays. Methods. 2005;37:208–15.
20. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K,
Yatani H, Yoneda T. Zoledronic acid delays wound healing of the tooth
extraction socket, inhibits oral epithelial cell migration, and promotes
proliferation and adhesion to hydroxyapatite of oral bacteria, without
causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 2010;28:
165–75.
21. Zhang Q, Yan HB, Wang J, Cui SJ, Wang XQ, Jiang YH, Feng L, Yang PY, Liu
F. Chromatin remodeling gene AT-rich interactive domain-containing
protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA
and PDK1. Oncotarget. 2016;7:46127–41.
22. Miao HL, Pan ZJ, Lei CJ, Wen JY, Li MY, Liu ZK, Qiu ZD, Lin MZ, Chen NP,
Chen M. Knockdown of GPC3 inhibits the proliferation of Huh7
hepatocellular carcinoma cells through down-regulation of YAP. J Cell
Biochem. 2013;114:625–31.
23. Ning BF, Ding J, Yin C, Zhong W, Wu K, Zeng X, Yang W, Chen YX, Zhang
JP, Zhang X, Wang HY, Xie WF. Hepatocyte nuclear factor 4 alpha
suppresses the development of hepatocellular carcinoma. Cancer Res. 2010;
70:7640–51.
24. Xu S, Wen Z, Jiang Q, Zhu L, Feng S, Zhao Y, Wu J, Dong Q, Mao J, Zhu Y.
CD58, a novel surface marker, promotes self-renewal of tumor-initiating
cells in colorectal cancer. Oncogene. 2015;34:1520–31.
25. Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X. MicroRNA-520e suppresses
growth of hepatoma cells by targeting the NF-kappaB-inducing kinase (NIK).
Oncogene. 2012;31:3607–20.
26. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M,
Hernandez-Boussard T, Brooks JD, Pollack JR. Genomic profiling reveals
alternative genetic pathways of prostate tumorigenesis. Cancer Res.
2007;67:8504–10.
27. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH.
PID: the Pathway Interaction Database. Nucleic Acids Res. 2009;37:D674–9.
28. Theocharis SE, Margeli AP, Koutselinis A. Metallothionein: a multifunctional
protein from toxicity to cancer. Int J Biol Markers. 2003;18:162–9.
29. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N,
Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor
suppressor gene in human hepatocellular carcinoma using a novel method
of double combination array analysis. Int J Oncol. 2009;35:477–83.
30. Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D. Metallothionein-1G
Facilitates Sorafenib Resistance through Inhibition of Ferroptosis.
Hepatology. 2016;64:488–500.
31. Mehrian-Shai R, Yalon M, Simon AJ, Eyal E, Pismenyuk T, Moshe I,
Constantini S, Toren A. High metallothionein predicts poor survival in
glioblastoma multiforme. BMC Med Genomics. 2015;8:68.
32. Tian ZQ, Xu YZ, Zhang YF, Ma GF, He M, Wang GY. Effects of
metallothionein-3 and metallothionein-1E gene transfection on
proliferation, cell cycle, and apoptosis of esophageal cancer cells.
Genet Mol Res. 2013;12:4595–603.
33. Pan Y, Huang J, Xing R, Yin X, Cui J, Li W, Yu J, Lu Y. Metallothionein 2A
inhibits NF-kappaB pathway activation and predicts clinical outcome
segregated with TNM stage in gastric cancer patients following radical
resection. J Transl Med. 2013;11:173.
34. Otsuka T, Hamada A, Iguchi K, Usui S, Hirano K. Suppression of
metallothionein 3 gene expression by androgen in LNCaP prostate cancer
cells. Biomed Rep. 2013;1:614–8.
35. Liang GY, Lu SX, Xu G, Liu XD, Li J, Zhang DS. Expression of metallothionein
and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues.
World J Surg Oncol. 2013;11:199.
Zheng et al. BMC Cancer  (2017) 17:161 Page 10 of 11
36. Kim HG, Kim JY, Han EH, Hwang YP, Choi JH, Park BH, Jeong HG.
Metallothionein-2A overexpression increases the expression of matrix
metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett.
2011;585:421–8.
37. Lai Y, Lim D, Tan PH, Leung TK, Yip GW, Bay BH. Silencing the
Metallothionein-2A gene induces entosis in adherent MCF-7 breast cancer
cells. Anat Rec (Hoboken). 2010;293:1685–91.
38. Pontes HA, de Aquino Xavier FC, da Silva TS, Fonseca FP, Paiva HB, Pontes
FS, dos Santos Pinto Jr D. Metallothionein and p-Akt proteins in oral
dysplasia and in oral squamous cell carcinoma: an immunohistochemical
study. J Oral Pathol Med. 2009;38:644–50.
39. Lim D, Jocelyn KM, Yip GW, Bay BH. Silencing the Metallothionein-2A gene
inhibits cell cycle progression from G1- to S-phase involving ATM and
cdc25A signaling in breast cancer cells. Cancer Lett. 2009;276:109–17.
40. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F,
Pilotti S, Pierotti MA, Greco A. Metallothionein 1G acts as an oncosupressor
in papillary thyroid carcinoma. Lab Invest. 2008;88:474–81.
41. Fan LZ, Cherian MG. Potential role of p53 on metallothionein induction in
human epithelial breast cancer cells. Br J Cancer. 2002;87:1019–26.
42. Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, Chen C, Zhang X, Esser
KA, Cohen DA, Evers BM, Jiang J, Spear BT. Targeting the Wnt/beta-catenin
signaling pathway in liver cancer stem cells and hepatocellular carcinoma
cell lines with FH535. PLoS One. 2014;9:e99272.
43. Park NR, Cha JH, Jang JW, Bae SH, Jang B, Kim JH, Hur W, Choi JY, Yoon SK.
Synergistic effects of CD44 and TGF-beta1 through AKT/GSK-3beta/beta-
catenin signaling during epithelial-mesenchymal transition in liver cancer
cells. Biochem Biophys Res Commun. 2016;477:568–74.
44. Zhou S, Yin X, Zheng Y, Miao X, Feng W, Cai J, Cai L. Metallothionein
prevents intermittent hypoxia-induced cardiac endoplasmic reticulum stress
and cell death likely via activation of Akt signaling pathway in mice. Toxicol
Lett. 2014;227:113–23.
45. Luo K, Long H, Xu B, Luo Y. Metallothionein ameliorates burn sepsis partly
via activation of Akt signaling pathway in mice: a randomized animal study.
World J Emerg Surg. 2015;10:53.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zheng et al. BMC Cancer  (2017) 17:161 Page 11 of 11
